NASDAQ:RXDX • US74349U1088
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PROMETHEUS BIOSCIENCES INC (RXDX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-05-10 | RBC Capital | Maintains | Sector Perform |
| 2023-05-10 | Jefferies | Downgrade | Buy -> Hold |
| 2023-04-18 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2023-04-18 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2023-04-18 | Credit Suisse | Downgrade | Outperform -> Neutral |
| 2023-04-18 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-04-17 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023-04-17 | Stifel | Downgrade | Buy -> Hold |
| 2023-03-06 | Guggenheim | Maintains | Buy |
| 2023-03-01 | Oppenheimer | Maintains | Outperform |
| 2023-03-01 | Credit Suisse | Maintains | Outperform |
| 2023-01-31 | Goldman Sachs | Maintains | Buy |
| 2022-12-08 | BTIG | Maintains | Buy |
| 2022-12-08 | Oppenheimer | Maintains | Outperform |
| 2022-12-08 | RBC Capital | Maintains | Outperform |
| 2022-12-08 | Credit Suisse | Maintains | Outperform |
| 2022-11-01 | Stifel | Maintains | Buy |
| 2022-10-04 | Oppenheimer | Maintains | Outperform |
| 2022-10-04 | RBC Capital | Maintains | Outperform |
| 2022-10-03 | BTIG | Maintains | Buy |
| 2022-08-29 | Wells Fargo | Maintains | Overweight |
| 2022-08-29 | Piper Sandler | Maintains | Overweight |
| 2022-08-12 | SVB Leerink | Maintains | Outperform |
| 2022-08-12 | Credit Suisse | Maintains | Outperform |
| 2022-07-20 | Goldman Sachs | Initiate | Buy |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.23M 9.82% | 3.129M 154.39% | 6.809M 117.61% | 2.094M -69.25% | 1.88M -10.22% | 90.343M 4,705.48% | 263.3M 191.44% | 616.43M 134.12% | 1.291B 109.43% | 1.963B 52.05% | 2.802B 42.74% | |
| EBITDA YoY % growth | -28.9M -81.42% | -87.545M -202.92% | -145.149M -65.80% | -202.449M -39.48% | -237.917M -17.52% | -279.194M -17.35% | -277.914M 0.46% | 224.54M 180.79% | 872.13M 288.41% | 1.942B 122.67% | 2.719B 40.01% | |
| EBIT YoY % growth | -29.01M -81.65% | -87.803M -202.66% | -145.778M -66.03% | -206.223M -41.46% | -253.212M -22.79% | -303.04M -19.68% | -337.811M -11.47% | 125.57M 137.17% | 783.23M 523.74% | 1.48B 88.96% | 2.145B 44.93% | |
| Operating Margin | -2,358.54% | -2,806.10% | -2,140.96% | -9,848.27% | -13,468.74% | -335.43% | -128.30% | 20.37% | 60.67% | 75.39% | 76.55% | |
| EPS YoY % growth | N/A | -3.63 | -3.48 4.13% | -4.07 -16.90% | -4.66 -14.42% | -5.40 -15.99% | -5.98 -10.70% | 2.57 143.00% | 10.60 312.40% | 16.30 53.76% | 22.46 37.78% |
All data in USD
| Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.95 -10.54% | -1.00 -11.52% | -1.12 -24.89% | -0.91 -5.56% | -0.93 2.36% | -0.95 5.49% | -0.97 13.79% |
| Revenue Q2Q % growth | 616.08K -51.45% | 657.135K -32.11% | 659.94K 1.06% | -100.00% | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | -48.034M -42.45% | -51.809M -36.46% | -70.182M -72.43% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -48.365M -42.38% | -51.01M -32.90% | -56.777M -37.37% | -51.878M -6.52% | -53.059M -9.71% | -54.565M -6.97% | -56.122M 1.15% |
All data in USD
15 analysts have analysed RXDX and the average price target is 198.9 USD. This implies a price decrease of -0.51% is expected in the next year compared to the current price of 199.92.
The consensus EPS estimate for the next earnings of PROMETHEUS BIOSCIENCES INC (RXDX) is -0.95 USD and the consensus revenue estimate is 616.08K USD.
The expected long term growth rate for PROMETHEUS BIOSCIENCES INC (RXDX) is 136.24%.